Pulse Biosciences (NASDAQ:PLSE) Given New $74.00 Price Target at Canaccord Genuity Group

Pulse Biosciences (NASDAQ:PLSE) had its price objective boosted by equities research analysts at Canaccord Genuity Group from $58.00 to $74.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group‘s price target points to a potential upside of 42.42% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on PLSE. BTIG Research started coverage on shares of Pulse Biosciences in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price target for the company. Freedom Capital raised Pulse Biosciences to a “strong-buy” rating in a research note on Wednesday, September 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. Finally, Needham & Company LLC lifted their target price on Pulse Biosciences from $58.00 to $64.00 and gave the company a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $66.60.

Pulse Biosciences Trading Down 2.1%

PLSE stock traded down $1.11 during trading on Friday, hitting $51.96. 255,516 shares of the company’s stock were exchanged, compared to its average volume of 390,012. The business has a 50-day moving average price of $51.45 and a two-hundred day moving average price of $32.08. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of -44.20 and a beta of 1.65. Pulse Biosciences has a 52-week low of $12.56 and a 52-week high of $58.90.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.52 million. During the same quarter in the prior year, the company earned ($0.29) earnings per share. The business’s revenue for the quarter was down 54.1% on a year-over-year basis. On average, equities research analysts anticipate that Pulse Biosciences will post -1.34 earnings per share for the current fiscal year.

Insider Activity at Pulse Biosciences

In other news, COO Liane Teplitsky bought 1,001 shares of the stock in a transaction dated Tuesday, September 1st. The shares were acquired at an average price of $49.95 per share, with a total value of $49,999.95. Following the completion of the acquisition, the chief operating officer directly owned 4,095 shares in the company, valued at approximately $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have acquired 4,095 shares of company stock valued at $199,931. 74.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC lifted its position in Pulse Biosciences by 844.6% in the third quarter. Sterling Capital Management LLC now owns 614 shares of the company’s stock valued at $31,000 after purchasing an additional 549 shares during the period. Bender Robert & Associates purchased a new stake in Pulse Biosciences in the 3rd quarter valued at approximately $379,000. Axxcess Wealth Management LLC acquired a new position in Pulse Biosciences during the 3rd quarter worth approximately $242,000. Formula Growth Ltd. acquired a new position in Pulse Biosciences during the 2nd quarter worth approximately $832,000. Finally, Panoramic Capital LLC acquired a new position in Pulse Biosciences during the 2nd quarter worth approximately $2,719,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of the company’s nanosecond pulsed field ablation (nsPFA) treatment were described as positive, adding support for its thyroid-treatment program. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results
• Positive Sentiment: Needham raised its price target to $64 from $58 and maintained a Buy rating, signaling greater analyst optimism. The company also said it completed enrollment in its U.S. pivotal IDE study three months ahead of schedule. Needham & Company recommendations Business updates and third-quarter results
• Negative Sentiment: Q3 revenue was $400,000, below the roughly $521,000 analyst estimate and down 54.1% year over year. The $0.32-per-share loss was also slightly wider than the $0.31 consensus cited in the earnings report, highlighting limited current revenue and continued losses. Article: Pulse Biosciences Reports Q3 Loss, Misses Revenue Estimates
• Negative Sentiment: Management expects quarterly non-GAAP expenses to rise 15%–25% and is targeting CE Mark approval in Q4 2027. The spending outlook could weigh on near-term profitability, while the regulatory timeline indicates commercialization remains some distance away. Article: Expense outlook and CE Mark target

About Pulse Biosciences

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.